CPRX - Catalyst Pharmaceuticals Non-GAAP EPS of $0.49 beats by $0.48 revenue of $102.7M beats by $2.33M
2023-11-08 16:38:22 ET
More on Catalyst Pharmaceuticals
- Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity
- Catalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent Perils
- Catalyst Pharmaceuticals Q3 2023 Earnings Preview
- FDA approves Catalyst, Santhera drug Agamree for Duchenne MD
- Seeking Alpha’s Quant Rating on Catalyst Pharmaceuticals
For further details see:
Catalyst Pharmaceuticals Non-GAAP EPS of $0.49 beats by $0.48, revenue of $102.7M beats by $2.33M